Your search for esrd returned 89 results

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week

In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.

Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.

New study is the first to characterize pegloticase use in the dialysis population.

EndoClot PHS is a single-use device consisting of a starch-based powder hemostat to control bleeding in the GI tract.

The FDA has granted Priority Review to dapagliflozin (Farxiga) for the treatment of new or worsening CKD.

The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.

Despite favorable efficacy data, the HIF-PHI failed to demonstrate noninferiority to the ESA in patients with CKD with respect to the primary MACE safety endpoint.

The multicenter, event-driven, double-blind, placebo-controlled trial compared the effect of dapagliflozin to placebo on renal outcomes and cardiovascular mortality in patients with CKD.